Systematic comparison of methods for determining the in vivo biodistribution of porous nanostructured injectable inorganic particles

Nizzero, Sara; Feng, Lei; Zhang, Guodong; Venuta, Alessandro; Borsoi, Carlotta; Mai, Junhua; Shen, Haifa; Wolfram, Joy; Li, Zheng; Blanco, Elvin; Ferrari, Mauro

doi:10.1016/j.actbio.2019.08.002

Cited by 8 publications

(9 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This ex vivo study revealed similar accumulation between lung and liver tissues, followed by spleen and kidneys, in contrast to data collected at similar time points via in vivo measurements that showed the highest accumulation occurs in lungs, followed by liver, kidneys, and then spleen. In a different study, Nizzero et al () also observed tissue attenuation effects in IVOI by directly comparing biodistribution of the fluorescent porous silica microdisks as estimated with IVIS Spectrum with the percent of injected dose (%ID) calculated by fluorescence measured in homogenized organs (Figure d). Notably, the two techniques differ in their ability to remove bias due to tissue attenuation of fluorescent signal.…”

Section: State‐of‐the‐art Imaging Modalities For Nps and Mabsmentioning

confidence: 96%

Section: State‐of‐the‐art Imaging Modalities For Nps and Mabsmentioning

confidence: 99%

“…Despite wide use in preclinical studies, non‐invasive optical imaging methods suffer from the unavoidable attenuation effects due to interaction of emitted light with biological matter (Nizzero et al, ). While optical imaging resolution can be pushed down to the Abbe diffraction limit (Figure c) for confocal microscopy setups, the resolution for in vivo IVOI is generally poorer (Figure ) (Arms et al, ).…”

Section: State‐of‐the‐art Imaging Modalities For Nps and Mabsmentioning

confidence: 99%

“…This is not possible with IVOI, so relative units (such as radiance) must be used for comparison. Thus, while a helpful tool to quickly compare in vivo targeting capabilities and PK of macromolecules and different compounds (Arms et al, ), the validity of noninvasive in vivo optical imaging methods to evaluate biodistribution may likely be considered semi‐quantitative at best (Nizzero et al, ).…”

Section: State‐of‐the‐art Imaging Modalities For Nps and Mabsmentioning

confidence: 99%

See 3 more Smart Citations

Image‐guided mathematical modeling for pharmacological evaluation of nanomaterials and monoclonal antibodies

Dogra

Butner

Nizzero

et al. 2020

WIREs Nanomed Nanobiotechnol

Self Cite

View full text Add to dashboard Cite

While plasma concentration kinetics has traditionally been the predictor of drug pharmacological effects, it can occasionally fail to represent kinetics at the site of action, particularly for solid tumors. This is especially true in the case of delivery of therapeutic macromolecules (drug‐loaded nanomaterials or monoclonal antibodies), which can experience challenges to effective delivery due to particle size‐dependent diffusion barriers at the target site. As a result, disparity between therapeutic plasma kinetics and kinetics at the site of action may exist, highlighting the importance of target site concentration kinetics in determining the pharmacodynamic effects of macromolecular therapeutic agents. Assessment of concentration kinetics at the target site has been facilitated by non‐invasive in vivo imaging modalities. This allows for visualization and quantification of the whole‐body disposition behavior of therapeutics that is essential for a comprehensive understanding of their pharmacokinetics and pharmacodynamics. Quantitative non‐invasive imaging can also help guide the development and parameterization of mathematical models for descriptive and predictive purposes. Here, we present a review of the application of state‐of‐the‐art imaging modalities for quantitative pharmacological evaluation of therapeutic nanoparticles and monoclonal antibodies, with a focus on their integration with mathematical models, and identify challenges and opportunities. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Diagnostic Tools > in vivo Nanodiagnostics and Imaging Nanotechnology Approaches to Biology > Nanoscale Systems in Biology

show abstract

Section: State‐of‐the‐art Imaging Modalities For Nps and Mabsmentioning

confidence: 96%

Section: State‐of‐the‐art Imaging Modalities For Nps and Mabsmentioning

confidence: 99%

Section: State‐of‐the‐art Imaging Modalities For Nps and Mabsmentioning

confidence: 99%

Section: State‐of‐the‐art Imaging Modalities For Nps and Mabsmentioning

confidence: 99%

See 2 more Smart Citations

Image‐guided mathematical modeling for pharmacological evaluation of nanomaterials and monoclonal antibodies

Dogra

Butner

Nizzero

et al. 2020

WIREs Nanomed Nanobiotechnol

Self Cite

View full text Add to dashboard Cite

show abstract

“…OraEx4 or Alexa 594-LCFA-Ex4 (1 mg/kg) was administered to C57BL/6 mice (male, 5 to 6 weeks old) alone or in combination with phloretin (50 mg/kg) via oral gavage. Mice were euthanized, and major organs were harvested at 1, 2, 4, 8, and 12 hours after oral gavage for fluorescence imaging using an IVIS-200 in vivo imaging system (PerkinElmer) (46). Quantitative analysis of fluorescence in organs was performed using Living Image Software 4.2 (Caliper Life Sciences, Hopkinton USA).…”

Section: Sample Preparation For Temmentioning

confidence: 99%

Molecular targeting of FATP4 transporter for oral delivery of therapeutic peptide

Nizzero

Goel

et al. 2020

Sci. Adv.

Self Cite

View full text Add to dashboard Cite

Low oral bioavailability of peptide drugs has limited their application to parenteral administration, which suffers from poor patient compliance. Here, we show that molecular targeting of the FATP4 transporter is an effective approach to specifically transport long-chain fatty acid (LCFA)–conjugated peptides across the enterocytic membrane and, thus, enables oral delivery of drug peptides. We packaged LCFA-conjugated exendin-4 (LCFA-Ex4) into liposomes and coated with chitosan nanoparticles to form an orally deliverable Ex4 (OraEx4). OraEx4 protected LCFA-Ex4 from damage by the gastric fluid and released LCFA-Ex4 in the intestinal cavity, where LCFA-Ex4 was transported across the enterocyte membrane by the FAPT4 transporter. OraEx4 had a high bioavailability of 24.8% with respect to subcutaneous injection and exhibited a substantial hypoglycemic effect in murine models of diabetes mellitus. Thus, molecular targeting of the FATP4 transporter enhances oral absorption of therapeutic peptides and provides a platform for oral peptide drug development.

show abstract

Radiolabeled porous silicon for nuclear imaging and theranostic applications

Sarparanta¹,

Airaksinen²

2021

Porous Silicon for Biomedical Applications

View full text Add to dashboard Cite

Systematic comparison of methods for determining the in vivo biodistribution of porous nanostructured injectable inorganic particles

Cited by 8 publications

References 61 publications

Image‐guided mathematical modeling for pharmacological evaluation of nanomaterials and monoclonal antibodies

Image‐guided mathematical modeling for pharmacological evaluation of nanomaterials and monoclonal antibodies

Molecular targeting of FATP4 transporter for oral delivery of therapeutic peptide

Radiolabeled porous silicon for nuclear imaging and theranostic applications

Contact Info

Product

Resources

About